Liver transplantation is now the standard of care for hepatocellular carcinoma (HCC) which meet selected criteria. However, there is rapidly evolving evidence showing that this complex operation can be performed for other liver malignancies, including colorectal liver metastasis, selected non-colorectal liver metastasis, biliary malignancies and others. There is much to understand in the field of transplant oncology, including the ideal selection criteria for liver transplant for these liver malignancies, the roles of systemic therapy and immunotherapy, tailoring implementation immunosuppressants in transplant oncology, and more. In this thematic series, we will attempt to provide a comprehensive assessment of the issues revolving transplant oncology.
In this thematic study, we wish to gather the most updated studies or reviews of related topics as listed below to provide a comprehensive understanding in relation to the field of transplant oncology. The concept of performing liver transplants for liver cancers, particularly metastatic cancers to the liver etc., is not new, but the efficacy of this treatment has shown recent successes and is developing rapidly all over the world. The scientific reasons behind in this success, as well as the crucial areas to investigate which include the influence of systemic therapy, management of immunotherapy in liver transplantation, influence of microbiome in these conditions in the outcomes of liver transplantation, as well as the effects on immunosuppressants in this specific subgroup, are all important questions to be answered.
This Research Topic welcomes submissions of Original Research, and Review articles that cover aspects including but are not limited to the following topics:
- Liver transplantation for HCC – improving selection and expanding criteria, and defining the contraindications with immunotherapy.
- Colorectal Liver Metastasis – An evolving indication for LT – Selection and Future Directions.
- Understanding the tumor microenvironment and influence of microbiome in Transplant Oncology
- Liver transplantation in Neuroendocrine Liver Metastasis
- Liver transplantation for Gastrointestinal Stromal Tumors
- Liver transplantation for Hilar Cholangiocarcinoma
- Liver transplantation for Intrahepatic Cholangiocarcinoma
- Liver transplantation for other rarer Liver Tumors (Hepatoblastoma, HEHE, etc.)
- Understanding the molecular biology in selecting candidates in Transplant Oncology
- Tailoring Immunosuppressants in Transplant Oncology
- Immune checkpoint blockade & immunotherapy in liver transplant recipients
- Host & donor immunological determinants of outcomes of liver transplantation in cancer
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Liver transplantation is now the standard of care for hepatocellular carcinoma (HCC) which meet selected criteria. However, there is rapidly evolving evidence showing that this complex operation can be performed for other liver malignancies, including colorectal liver metastasis, selected non-colorectal liver metastasis, biliary malignancies and others. There is much to understand in the field of transplant oncology, including the ideal selection criteria for liver transplant for these liver malignancies, the roles of systemic therapy and immunotherapy, tailoring implementation immunosuppressants in transplant oncology, and more. In this thematic series, we will attempt to provide a comprehensive assessment of the issues revolving transplant oncology.
In this thematic study, we wish to gather the most updated studies or reviews of related topics as listed below to provide a comprehensive understanding in relation to the field of transplant oncology. The concept of performing liver transplants for liver cancers, particularly metastatic cancers to the liver etc., is not new, but the efficacy of this treatment has shown recent successes and is developing rapidly all over the world. The scientific reasons behind in this success, as well as the crucial areas to investigate which include the influence of systemic therapy, management of immunotherapy in liver transplantation, influence of microbiome in these conditions in the outcomes of liver transplantation, as well as the effects on immunosuppressants in this specific subgroup, are all important questions to be answered.
This Research Topic welcomes submissions of Original Research, and Review articles that cover aspects including but are not limited to the following topics:
- Liver transplantation for HCC – improving selection and expanding criteria, and defining the contraindications with immunotherapy.
- Colorectal Liver Metastasis – An evolving indication for LT – Selection and Future Directions.
- Understanding the tumor microenvironment and influence of microbiome in Transplant Oncology
- Liver transplantation in Neuroendocrine Liver Metastasis
- Liver transplantation for Gastrointestinal Stromal Tumors
- Liver transplantation for Hilar Cholangiocarcinoma
- Liver transplantation for Intrahepatic Cholangiocarcinoma
- Liver transplantation for other rarer Liver Tumors (Hepatoblastoma, HEHE, etc.)
- Understanding the molecular biology in selecting candidates in Transplant Oncology
- Tailoring Immunosuppressants in Transplant Oncology
- Immune checkpoint blockade & immunotherapy in liver transplant recipients
- Host & donor immunological determinants of outcomes of liver transplantation in cancer
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
